2025 年第三次临时股东大会会议资料 天域生物科技股份有限公司 2025 年第三次临时股东大会会议资料 二 O 二五年九月十一日 2025 年第三次临时股东大会会议资料 天域生物科技股份有限公司 2025 年第三次临时股东大会会议资料目录 一、本次会议设立股东大会会务组，具体负责会议期间的组织及 相关会务工作。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法 权益，务请出席大会的股东或股东代理人（以下统称"股东"）及相关 人员准时到达会场签到确认参会资格。股东参会登记当天没有通过电 话、邮件或传真方式登记的，不在签到表上登记签到的，或会议正式 开始后没有统计在会议公布股权数之内的股东或股东代理人，不参加 表决和发言。 三、请参会人员自觉遵守会场秩序，进入会场后，请关闭手机或 调至振动状态。 四、股东在会议召开期间准备发言的，请在会议开始前到大会会 务组登记并填写"股东大会发言登记表"。股东临时要求发言或就相关 问题提出质询的，应当先向大会会务组申请，经大会主持人许可后方 可。 | 年第三次临时股东大会会议须知 2 | 2025 | | --- | --- | | 年第三次临时股东大会会议议程 4 ...

Core Insights - Tianyu Bio (603717.SH) reported a total operating revenue of 412 million yuan for the first half of 2025, with a net profit attributable to shareholders of 10.82 million yuan, marking an increase of 4.59 million yuan compared to the same period last year, representing a year-on-year growth of 73.68% [1] - The company achieved a net cash inflow from operating activities of 89.83 million yuan, an increase of 31.90 million yuan from the same period last year, reflecting a year-on-year growth of 55.07% [1] Financial Performance - The latest debt-to-asset ratio stands at 75.62%, a decrease of 0.29 percentage points from the previous quarter [3] - The gross profit margin is reported at 14.64%, ranking 10th among disclosed peers [3] - Return on equity (ROE) is at 2.04%, an increase of 1.09 percentage points year-on-year, ranking 11th among disclosed peers [3] - The diluted earnings per share (EPS) is 0.04 yuan, an increase of 0.02 yuan compared to the same period last year, reflecting a year-on-year growth of 73.49% [3] - The total asset turnover ratio is 0.13 times, remaining stable compared to the same period last year, with a year-on-year increase of 2.57% [3] - The inventory turnover ratio is reported at 1.66 times [3] Shareholder Structure - The number of shareholders is 20,200, with the top ten shareholders holding a total of 115 million shares, accounting for 39.53% of the total share capital [3] - The top shareholders and their respective holdings are as follows: - T: 12.84% - Shi Dongwei: 11.15% - Shenzhen Zeyuan Private Securities Fund Management Co., Ltd.: 7.58% - Mao Shiqi: 2.67% - Ren Chao: 0.98% - Li Jixiang: 0.97% - Shanghai Luran Investment Management Co., Ltd.: 0.90% - Cha Qizuo: 0.89% - Ding Tai Sifang (Shenzhen) Private Fund Management Co., Ltd.: 0.80% - Barclays Bank PLC: 0.76% [3]

Core Viewpoint - Tianyu Biological (603717) has experienced a decline in stock price and market capitalization, with significant changes in shareholder structure and financial performance reported in recent disclosures [1][2][3]. Group 1: Stock Performance - As of August 29, 2025, Tianyu Biological's stock closed at 8.26 yuan, down 3.73% from the previous week [1]. - The stock reached a peak of 9.25 yuan on August 25, 2025, and a low of 8.09 yuan on August 28, 2025 [1]. - The company's current total market capitalization is 2.397 billion yuan, ranking 23rd in the aquaculture sector and 4866th in the A-share market [1]. Group 2: Shareholder Changes - As of June 30, 2025, the number of shareholders decreased to 20,200, a reduction of 413 shareholders or 2.0% from March 31, 2025 [1]. - The average number of shares held per shareholder increased from 14,100 to 14,400, with an average holding value of 104,100 yuan [1]. - The actual controller of the company has changed to Luo Weiguo following the termination of the concerted action relationship with Shi Dongwei, who relinquished voting rights for 32,338,800 shares [3]. Group 3: Financial Performance - The company's mid-year report for 2025 shows a main revenue of 412 million yuan, a year-on-year decrease of 2.62% [2]. - The net profit attributable to shareholders increased to 10.818 million yuan, a year-on-year rise of 73.68% [2]. - The company reported a negative non-recurring net profit of 19.3017 million yuan, a significant decline of 528.8% year-on-year [2]. Group 4: Corporate Announcements - On August 25, 2025, the company approved a plan to issue A-shares to specific investors, with a maximum of 71,028,297 shares at a price of 6.55 yuan per share, aiming to raise up to 465.2353 million yuan for working capital and debt repayment [3]. - The company has committed to a shareholder return plan for 2025-2027, promising annual cash dividends of at least 10% of distributable profits, and at least 80% when there are no major expenditures [3]. - The company has not faced regulatory penalties in the past five years and has rectified previous issues related to information disclosure and impairment provisions [3].

Core Viewpoint - Tianyu Biological (603717) reported a mixed financial performance for the first half of 2025, with a decline in total revenue but a significant increase in net profit compared to the previous year [1] Financial Performance Summary - Total revenue for the first half of 2025 was 412 million yuan, a decrease of 2.62% year-on-year [1] - Net profit attributable to shareholders reached 10.82 million yuan, an increase of 73.68% year-on-year [1] - In Q2 2025, total revenue was 187 million yuan, down 11.87% year-on-year, while net profit was -2.95 million yuan, a decline of 5.38% year-on-year [1] - The gross margin was 14.63%, a decrease of 1.97% year-on-year, while the net margin improved to 7.73%, an increase of 138.86% year-on-year [1] - Total operating expenses (selling, administrative, and financial) amounted to 58.23 million yuan, accounting for 14.12% of revenue, an increase of 19.65% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents decreased to 158 million yuan, down 12.17% year-on-year [1] - Accounts receivable stood at 340 million yuan, a decrease of 4.45% year-on-year, representing 42.36% of total revenue [1] - Interest-bearing liabilities decreased to 1.248 billion yuan, down 8.67% year-on-year [1] - Book value per share was 1.83 yuan, a decrease of 18.84% year-on-year [1] - Earnings per share increased to 0.04 yuan, up 73.49% year-on-year [1] - Operating cash flow per share improved to 0.31 yuan, an increase of 55.07% year-on-year [1] Business Evaluation - The company's historical return on invested capital (ROIC) has been generally low, with a median of 6.66% since its listing, and a particularly poor ROIC of -24.52% in 2023 [1] - The company has reported losses in five out of its seven annual reports since going public, indicating a challenging financial history [1]

格隆汇8月29日丨天域生物(603717.SH)发布中报，2025上半年实现营业总收入4.12亿元，同比下降 2.62%；归属母公司股东净利润1081.8万元，同比增长73.68%；基本每股收益为0.0373元。 ...

从股价来看，2025年3月31日至2025年6月30日，天域生物区间涨幅为0.14%，在此期间股东户数减少 413.0户，减幅为2.0%。 证券之星消息，近日天域生物披露，截至2025年6月30日公司股东户数为2.02万户，较3月31日减少413.0 户，减幅为2.0%。户均持股数量由上期的1.41万股增加至1.44万股，户均持股市值为10.41万元。 在养殖业行业个股中，天域生物股东户数低于行业平均水平，截至6月30日，养殖业行业平均股东户数 为5.76万户。户均持股市值方面，养殖业行业A股上市公司户均持股市值为41.87万元，天域生物低于行 业平均水平。 | | | | 统计截止日 区间股价涨跌幅 股东户数 增减 增减比例 户均持股市值 (元) 户均持股数（股) | | | | --- | --- | --- | --- | --- | --- | | 2025-06-30 | 0.14% | 20200 -413 | -2.00% | 10.41万 | 1.44万 | | 2025-03-31 | -10.06% | 20613 -346 | -1.65% | 10.19万 | 1.41万 | | 20 ...

Group 1 - The company reported a slight decrease in revenue of 2.62% year-on-year, totaling 412 million yuan for the first half of 2025, while net profit attributable to shareholders increased significantly by 73.68% to 10.82 million yuan [1] - The company achieved a net cash flow from operating activities of 89.83 million yuan, reflecting a growth of 55.07% year-on-year, indicating ongoing improvement in operational performance [1] - The company is focusing on a development strategy centered around "ecology" and is actively pursuing a "digital intelligence" transformation to enhance business efficiency and quality [1] Group 2 - The company has expanded its ecological agriculture strategy by integrating biotechnology into the production and sales of red yeast products, health foods, and agricultural products, with red yeast product capacity increasing by 36.78 tons and sales revenue rising by 734.95 thousand yuan [2] - The company is exploring transitions into new energy and infrastructure sectors, particularly focusing on photovoltaic and energy storage projects, which serve as a supplement to its ecological environment engineering business [2] - The ecological energy business has signed contracts for several distributed photovoltaic power generation projects, generating green power revenue of 14.90 million yuan [2]

Core Viewpoint - Tianyu Bio (603717) reported a slight decrease in revenue but a significant increase in net profit for the first half of 2025, indicating a positive trend in operational performance [2] Group 1: Financial Performance - The company achieved operating revenue of 412 million yuan, a year-on-year decrease of 2.62% [2] - The net profit attributable to shareholders was 10.82 million yuan, a year-on-year increase of 73.68% [2] - The net cash flow from operating activities was 89.83 million yuan, reflecting a year-on-year growth of 55.07% [2] Group 2: Business Strategy - The company maintains a steady development strategy focused on "ecology" and aims for business upgrades through "digital intelligence" [2] - It is steadily developing its ecological agricultural and food business, including pig farming and agricultural product sales, while strategically shrinking its ecological environment business [2] - The company is actively embracing new production capabilities, such as artificial intelligence, to enhance quality and efficiency [2] Group 3: Agricultural Business Development - The company improved breeding efficiency and product quality through five key areas: biosecurity, herd health management, major disease prevention, breeding management, and production management [2] - It achieved pig sales of 204,200 heads, an increase of 21.52%, and pig farming revenue of 312 million yuan, an increase of 17.49% [2] Group 4: Product Expansion - The company is developing biotechnology-based red yeast products, health foods, and agricultural products, positioning healthy ecological food as a strategic breakthrough [3] - The production capacity of red yeast products increased by 36.78 tons, with sales revenue rising by 734.95 thousand yuan [3] Group 5: Renewable Energy Initiatives - The company is exploring transitions into renewable energy and new infrastructure, focusing on photovoltaic and energy storage solutions as part of its ecological environment engineering business [3] - It signed contracts for several distributed photovoltaic power generation projects, generating green power revenue of 14.89 million yuan [3]

Group 1 - The core viewpoint of the article highlights Tianyu Bio's strong performance in the first half of 2025, achieving a revenue of 412 million yuan and a net profit of 10.818 million yuan, representing a year-on-year growth of 73.68% [1] - The company is focusing on a "digital transformation" strategy to enhance quality and efficiency, actively embracing applications of artificial intelligence and optimizing resource allocation for the ecological agriculture and energy sectors [1] - In the ecological livestock business, the company sold 204,214 pigs, a year-on-year increase of 21.52%, generating 312 million yuan in revenue, which is a 17.49% increase compared to the previous year [1] Group 2 - The company is developing a series of red yeast products and health foods, positioning healthy ecological food as a strategic breakthrough to support its ecological agriculture strategy [2] - The production capacity of red yeast products increased by 36.78 tons year-on-year, with sales revenue rising by 734.95 thousand yuan [2] - In the ecological energy sector, the company has made progress in expanding its business, signing contracts for distributed photovoltaic power generation projects, achieving a green power revenue of 14.8976 million yuan from 6.30 MW of projects connected to the grid [2]

证券代码：603717 证券简称：天域生物 公告编号：2025-072 天域生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 天域生物科技股份有限公司（以下简称"公司"）第四届董事会第四十四次 会议（以下简称"本次会议"）通知于 2025 年 08 月 19 日以电子邮件方式发出， 本次会议于 2025 年 08 月 29 日上午 10:00 在公司会议室以现场结合通讯表决方 式召开。本次会议应到董事 9 人，实到董事 9 人。本次会议由公司董事长罗卫国 先生主持，公司部分高级管理人员列席会议。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》、 《公司章 二、董事会会议审议情况 本次会议审议并通过了如下议案： （一）《<2025 年半年度报告>及其摘要》 具体内容详见公司在上海证券交易所官方网站上发布的《2025 年半年度报 告》及《2025 年半年度报告摘要》。 表决结果：9 票同意、0 票反对、0 票弃权、0 票回避。 本议案已经第四届董事会审计委员会第二十六次会议事 ...